We scan new podcasts and send you the top 5 insights daily.
John Chatzko reported that 82% of baseline ctDNA-positive patients cleared ctDNA before surgery on EV+Pembro versus 67% on gem/cis. Among those clearers, two-year EFS was 81% versus 63%, suggesting EV+Pembro drives a deeper biologic response. That gap implies the quality, not just frequency, of clearance differs by regimen.
Not all ctDNA clearance is equal. Data from KEYNOTE-361 shows chemotherapy clears ctDNA more frequently (40%) but with poor correlation to outcomes. In contrast, immunotherapy clears ctDNA less often (11%), but those patients who do clear it experience brilliant, more durable outcomes, suggesting a different biological mechanism of response.
In patients achieving a complete response on EV-pembrolizumab, leading oncologists are using circulating tumor DNA (ctDNA) clearance in clinical practice to increase confidence and facilitate shared decision-making around stopping treatment, despite it not being standard of care.
The type of treatment inducing ctDNA clearance matters. Clearance from immunotherapy appears to be more permanent and strongly prognostic than clearance from chemotherapy, which can be transient. This suggests immunotherapy may achieve a more profound and lasting elimination of cancer cells versus cytotoxic agents.
KEYNOTE-522 data shows that achieving pathologic complete response (path CR) with pembrolizumab offers a greater survival benefit than achieving path CR with chemotherapy alone. This suggests immunotherapy provides a lasting benefit beyond just initial tumor eradication.
Tom noted post-surgery ctDNA positivity fell to 5% on EV+Pembro versus 15% on chemotherapy, and the chemo arm also declined. He suspects surgery accounts for only part of the drop, with delayed immune clearance from EV+Pembro contributing; the durability of response evolves over months. So the surgical effect is not the whole story.
At baseline, ctDNA positivity predicted worse two-year EFS in both arms, yet EV+Pembro still outperformed chemotherapy in positive and negative patients. The hosts found no predictive signal, and ctDNA-negative patients on chemotherapy still faced roughly 15–20% relapse risk, so baseline results should not guide de-escalation.
Unlike immunotherapy, where ctDNA clearance strongly predicts good outcomes, chemotherapy can cause a temporary decrease in ctDNA that doesn't correlate with long-term survival. This "smudging" effect complicates ctDNA interpretation for patients receiving chemo-immunotherapy combinations.
In neoadjuvant therapy, a patient's long-term outcome is better predicted by stopping tumor DNA shedding (ctDNA clearance) than by achieving pathologic complete response (pCR), the traditional gold standard. This redefines what constitutes a successful treatment response before surgery.
Tom said no pre-surgery ctDNA-positive patient achieved pCR in EV304 or Niagara. Among ctDNA-negative patients, pCR was 75% with EV+Pembro but roughly 50-50 with chemotherapy. That makes bladder-sparing risky while ctDNA remains positive; the test is not a green light for less local therapy.
Tom noted 24-month EFS was 94% in EV+Pembro patients who were ctDNA-negative at baseline and stayed negative, but John Chatzko cautioned that about a quarter of pre-surgery ctDNA-negative EV+Pembro patients still lacked pCR. They favored randomized de-escalation trials over routine treatment reduction; the high survival is real, but causal attribution is not.